Steve Schonfeld’s Grace Therapeutics GRCE Stock Holding History

Steve Schonfeld’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-604	Closed	-$71K	–	1586
2019 Q4	$71K	Buy	+604	New	+$59.7K	﹤0.01%	1221

Other funds holding GRCE

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

JLBC

J.L. Bainbridge & Co Sarasota, Florida $1.27B AUM 26.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

Steve Schonfeld's GRCE Position: Q1 2020 in Review

Steve Schonfeld sold out of Grace Therapeutics (GRCE) in Q1 2020, closing a stake of 604 shares — an estimated $71K sold.

Steve Schonfeld first reported a position in GRCE in Q4 2019 and held it in 1 quarter. The position peaked at $71K in Q4 2019. 26 funds tracked by Wall St. Rank hold GRCE as of Q1 2020.

Steve Schonfeld reported no remaining Grace Therapeutics position as of Q1 2020 after selling out during the quarter.
Steve Schonfeld sold 604 Grace Therapeutics shares in Q1 2020, an estimated $71K.
Steve Schonfeld first reported a position in Grace Therapeutics in Q4 2019 and held it in 1 quarter.
Steve Schonfeld's Grace Therapeutics position peaked at $71K in Q4 2019.
26 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2020, filed 15 May 2020.